Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MGNX logo MGNX
Upturn stock ratingUpturn stock rating
MGNX logo

MacroGenics Inc (MGNX)

Upturn stock ratingUpturn stock rating
$2.4
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/11/2025: MGNX (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 98.88%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/11/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 163.18M USD
Price to earnings Ratio -
1Y Target Price 7.38
Price to earnings Ratio -
1Y Target Price 7.38
Volume (30-day avg) 662040
Beta 2.08
52 Weeks Range 2.37 - 21.88
Updated Date 02/10/2025
52 Weeks Range 2.37 - 21.88
Updated Date 02/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.53

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -69.07%
Operating Margin (TTM) 48.95%

Management Effectiveness

Return on Assets (TTM) -22.15%
Return on Equity (TTM) -62.17%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3078036
Price to Sales(TTM) 1.15
Enterprise Value -3078036
Price to Sales(TTM) 1.15
Enterprise Value to Revenue 2.69
Enterprise Value to EBITDA -1.54
Shares Outstanding 62763400
Shares Floating 51742814
Shares Outstanding 62763400
Shares Floating 51742814
Percent Insiders 2.65
Percent Institutions 93.19

AI Summary

MacroGenics Inc. Overview:

Company Profile:

History and Background:

MacroGenics Inc. (NASDAQ: MGEN) was founded in 2000 and is headquartered in Rockville, Maryland. The company focuses on discovering and developing innovative antibody-based therapies for the treatment of cancer, autoimmune diseases, and infectious diseases. MacroGenics utilizes its proprietary DART® (Dual Affinity Re-Targeting) platform technology to create bispecific and trispecific antibody-based therapeutics.

Core Business Areas:

  • Oncology: Development of antibody-based therapies for the treatment of various cancers, such as solid tumors, hematologic malignancies, and immunotherapy.
  • Infectious Diseases: Focus on developing antibody-based therapies for infectious diseases like HIV and COVID-19.
  • Autoimmune Diseases: Targeting autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease.

Leadership and Corporate Structure:

  • President and Chief Executive Officer: Scott Koenig, M.D., Ph.D.
  • Executive Vice President and Chief Financial Officer: Patricia S. Conti
  • Senior Vice President and Chief Scientific Officer: Daniel A. Vallera, Ph.D.
  • Board of Directors: Comprises experienced leaders in the pharmaceutical and biotechnology industry.

Top Products and Market Share:

  • Margetuximab (Margenza®): A CD38-directed monoclonal antibody for the treatment of multiple myeloma, approved in the US and Europe. Holds a market share of approximately 10% in the US market for CD38-directed therapies.
  • Tecovirimat (TPOXX®): An antiviral drug for the treatment of smallpox, approved by the FDA.
  • MGD013: An investigational bispecific antibody targeting both B7-H3 and PD-L1, currently in Phase 2 clinical trials for various cancers.

Total Addressable Market:

The global market for oncology drugs is expected to reach $248.2 billion by 2025. The autoimmune disease market is projected to reach $235.5 billion by 2027.

Financial Performance:

Recent Financials:

  • Revenue: $69.3 million (2022)
  • Net Income: ($100.3 million) (2022)
  • Profit Margin: -144.6% (2022)
  • Earnings per Share (EPS): ($2.15) (2022)

Year-over-Year Performance:

  • Revenue has grown by 19% from 2021.
  • Net loss has increased from 2021.
  • Cash flow is negative, reflecting investments in R&D and clinical trials.

Dividends and Shareholder Returns:

  • Dividend History: MacroGenics does not currently pay dividends.
  • Shareholder Returns: Share price has declined significantly over the past year.

Growth Trajectory:

Historical Growth: Revenue has grown steadily over the past few years, driven by the launch of Margenza and the advancement of its pipeline.

Future Growth Projections: MacroGenics expects to achieve profitability in 2025, driven by Margenza sales and potential approval of other pipeline candidates.

Market Dynamics:

The pharmaceutical and biotechnology industry is highly competitive and constantly evolving. MacroGenics faces challenges from established players and innovative startups in the field of antibody-based therapies.

Key Competitors:

  • Amgen (AMGN)
  • AbbVie (ABBV)
  • Bristol Myers Squibb (BMY)
  • Gilead Sciences (GILD)
  • Regeneron (REGN)
  • Seagen (SGEN)
  • Immunomedics (IMMU)
  • ImmunoGen (IMGN)
  • Argenx (ARGX)

Potential Challenges and Opportunities:

  • Challenges: Competition, successful development and commercialization of pipeline candidates, regulatory hurdles, and intellectual property issues.
  • Opportunities: Growing demand for novel cancer therapies, expansion into new markets, potential partnerships with larger pharmaceutical companies.

Recent Acquisitions (last 3 years):

  • 2021: Acquired exclusive worldwide rights for the DART protein MGD023 from Xencor, Inc.
  • 2020: Acquired exclusive worldwide rights for the DART protein MGD013 from Xencor, Inc.
  • 2020: Acquired exclusive worldwide rights for the DART protein MGD019 from Xencor, Inc.

AI-Based Fundamental Rating:

MacroGenics receives a 5 out of 10 rating. While the company has promising pipeline candidates and a unique technology platform, it faces profitability challenges, competition, and market volatility.

Disclaimer:

This analysis is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About MacroGenics Inc

Exchange NASDAQ
Headquaters Rockville, MD, United States
IPO Launch date 2013-10-10
President, CEO & Director Dr. Scott Koenig M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 339
Full time employees 339

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​